Accendra Health (ACH) AI Stock Analysis

• Market Cap: $170.94M
• Dividend Yield: N/A
• Average Volume (3M): 1.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 23,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.25
• Shares Outstanding: 77,346,596
• 10 Day Avg. Volume: 1,105,922
• 30 Day Avg. Volume: 1,613,132
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.07
• Price to Sales (P/S): 0.00375
• P/FCF Ratio: -0.60
• Enterprise Value/Market Cap: 13.66
• Enterprise Value/Revenue: 0.35
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: -48.98
• 1Y Price Target: $3.50
• Price Target Upside: 58.37% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $2.00 ▼(-9.50% Downside)

Owens & Minor's overall stock score is primarily impacted by its poor financial performance, with significant challenges in revenue, profitability, and cash flow. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and no dividend yield. The earnings call provided some positive strategic shifts, but these are overshadowed by ongoing operational issues and financial instability.

Positive Factors

Strategic refocus to home-based care

The divestiture and shift to a Patient Direct/home-based care focus simplifies the business, concentrates resources on a structurally growing care channel, and should improve operational clarity. Over months this can increase margin stability and strategic agility.

Improving free cash flow in continuing operations

Positive free cash flow generation from continuing operations, sustained across multiple quarters, enhances the company’s ability to pay down debt and fund technology and automation investments, supporting financial flexibility and execution of the strategic pivot over the medium term.

Growth in specialized product categories

Outperformance in niche categories indicates exposure to durable demand drivers and potential for higher-margin sales. Concentrated growth in clinical specialty lines supports more predictable revenue and a defensible position within targeted patient-direct markets over coming quarters.

Negative Factors

Weak balance sheet and negative equity

Negative equity and historically high leverage materially constrain financial flexibility, raise refinancing and covenant risk, and limit capacity for strategic investments. This structural weakness increases vulnerability to revenue shocks and slows recovery timelines.

Sharp revenue decline and negative margins

Sustained revenue contraction and large negative margins undermine scale economics and the company’s ability to cover fixed costs. Without durable revenue stabilization, profitability recovery will be difficult, hampering reinvestment and long-term competitiveness.

Negative operating cash flow and EBITDA pressure

Negative operating cash flow and recent EBITDA decline indicate weak core cash conversion. This structural cash shortfall limits debt reduction and investment in automation/technology, increasing reliance on asset sales or external financing to fund operations.

Accendra Health Business Overview & Revenue Model

Company Description

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. The company operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment also supplies a range of other home medical equipment; and patient care products, including ostomy, wound care, urology, and incontinence and other products and services. The company serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Accendra Health, Inc. was formerly known as Owens & Minor, Inc. and changed its name Accendra Health, Inc. in December 2025. The company was founded in 1882 and is based in Glen Allen, Virginia.

How the Company Makes Money

Accendra Health Financial Statement Overview

Summary

Owens & Minor is facing significant financial challenges. The income statement shows declining revenues and negative profitability, while the balance sheet reflects high leverage and negative equity. Cash flow issues further exacerbate the situation, with negative operating cash flow in the TTM period. The company needs to address these financial difficulties to stabilize and improve its financial health.

Income Statement

Owens & Minor's income statement reveals significant challenges. The TTM data shows a sharp decline in revenue by 23.18%, and the company is experiencing negative margins across the board, with a net profit margin of -19.98% and an EBIT margin of -4.52%. This indicates substantial operational difficulties. Historically, the company had positive revenue growth and margins, but recent performance has deteriorated significantly.

Balance Sheet

The balance sheet is concerning, with a negative stockholders' equity in the TTM period, leading to an undefined debt-to-equity ratio. Historically, the debt-to-equity ratio was high, indicating significant leverage. The return on equity has turned negative, reflecting poor profitability and financial instability.

Cash Flow

Cash flow analysis shows a negative operating cash flow in the TTM period, indicating cash flow challenges. The free cash flow to net income ratio is relatively high at 90.92%, suggesting that despite losses, the company manages to generate some free cash flow. However, the overall cash flow situation is weak, with declining free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.71B	10.70B	10.33B	9.96B	9.79B	8.48B
Gross Profit	1.75B	2.22B	2.13B	1.83B	1.51B	1.28B
EBITDA	-47.67M	515.18M	390.57M	368.45M	415.46M	323.41M
Net Income	-1.34B	-362.69M	-41.30M	22.39M	221.59M	29.87M
Balance Sheet
Total Assets	4.04B	4.66B	5.09B	5.39B	3.54B	3.34B
Cash, Cash Equivalents and Short-Term Investments	32.84M	49.38M	243.04M	69.47M	55.71M	118.18M
Total Debt	2.20B	2.14B	2.41B	2.79B	1.15B	1.14B
Total Liabilities	4.47B	4.09B	4.17B	4.44B	2.60B	2.62B
Stockholders Equity	-429.51M	565.23M	924.17M	945.60M	938.50M	712.05M
Cash Flow
Free Cash Flow	-352.19M	-66.67M	532.82M	158.42M	74.49M	280.03M
Operating Cash Flow	-98.97M	161.50M	740.71M	325.01M	124.18M	339.22M
Investing Cash Flow	-192.88M	-116.53M	-137.25M	-1.80B	-53.63M	80.07M
Financing Cash Flow	262.48M	-267.60M	-417.33M	1.50B	-129.48M	-379.39M

Accendra Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%